In patients with GBM tumors of the classical or mesenchymal subtype, a reduction of NR3C2 also correlates with poor survival, whereas in patients with GBM tumors of the proneural type the very low expression of NR3C2 correlates with better survival. Here, NR3C2 is linked to glioblastoma.